Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology®
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that an application for a new clinical study at Uppsala University Hospital has been submitted. The study will assess intratumoral injections of NZ-DTX Depot, containing the cytotoxic agent docetaxel, in men with prostate cancer who are scheduled for prostatectomy. The trial is originated by the principal investigator of the trial, Dr Michael Häggman, Associate Professor at the Department of Surgical Sciences in Urology, Uppsala University Hospital.
The study is planned to start in mid of this year and it will enroll 10- 15 patients to be treated with NZ-DTX prior to planned surgery.
“The NanoZolid technology is suitable to combine with the MRI/TRUS injection technique for a high precision intratumoral delivery of NZ-DTX Depot. Treating patients prior to removal of the prostate gland will provide exhaustive information with regards to local effects in the tumor and surrounding tissue”, commented Dr Michael Häggman.
“We are very pleased to see that yet again our NanoZolid technology retains interest as NZ-DTX Depot for intratumoral injections in localized prostate cancer will be investigated. Dr Häggman has vast experience of local treatments of prostate cancer and this study will contribute to a stronger understanding of a broad range of oncology effects in prostate cancer tumors“, said Monica Wallter, CEO of LIDDS.
For more information, please contact:
Monica Wallter, CEO, +46 (0)737 07 09 22, e-mail: monica.wallter@liddspharma.com
The information was submitted for publication, through the agency of the aforementioned contact person, on April 16 at 09:00 CET.
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects for cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North Growth Market (LIDDS). Redeye AB is the Certified Adviser to LIDDS (+46 (0) 8 121 576 90, email: certifiedadviser@redeye.se) For more information, please visit www.liddspharma.com.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
EPH European Property Holdings PLC announces 2023 Year-End Result26.4.2024 23:55:00 CEST | Press release
26 April 2024, Limassol, Cyprus / Ad hoc announcement pursuant to Art. 53 LR BUSINESS HIGHLIGHTS 2023 Despite the challenging market environment, EPH European Property Holdings PLC (“EPH” or the “Company”) maintained operational stability in 2023. This success can be attributed to its established portfolio of high-quality properties in prime locations in Europe, and professional asset management. As a result, EPH once again achieved almost full occupancy throughout its European portfolio, and exceeded own expectations by increasing net rental income by 26 percent compared to the previous year.As of 31 December 2023, EPH’s real estate portfolio consisted of eight core assets (and one parking garage) in outstanding locations in Germany and Vienna, all of which meet high sustainability standards. Seven out of eight office and hotel buildings have already been awarded certificates in DGNB Platinum, DGNB Gold, or LEED Gold.A milestone in the operating business was the completion of the LASS
FRO – Filing of Annual Report26.4.2024 22:36:43 CEST | Press release
Frontline plc (the “Company”) announces the filing of its annual report for the year ended December 31, 2023. The annual report can be downloaded from the Company’s website www.frontlineplc.cy or from the link below. Additionally, shareholders can request a hard copy of our complete audited financial statements free of charge by writing to us at: John Kennedy 8 Iris Building, 7th floor, Flat/Office 740B, 3106, Limassol, Cyprus. or sending an e-mail to ir@frontmgt.no April 26, 2024 Frontline plc Limassol, Cyprus. Questions should be directed to: Lars H. Barstad: Chief Executive Officer, Frontline Management AS +47 23 11 40 00 Inger M. Klemp: Chief Financial Officer, Frontline Management AS +47 23 11 40 00 This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. Attachments 5493004BCIKYU1YL3H63-2023-12-31-enAnnual Report 2023
Kallelse till årsstämma 2024 i Fingerprint Cards AB (publ)26.4.2024 22:16:32 CEST | Pressemelding
Aktieägarna i Fingerprint Cards AB (publ), org. nr. 556154-2381 (”Bolaget” eller ”Fingerprint”), kallas härmed till årsstämma klockan 15.00 tisdagen den 28 maj 2024 på GT30 (mötesrum ”Bond”), Grev Turegatan 30 i Stockholm. Styrelsen har, i enlighet med Bolagets bolagsordning, beslutat att aktieägarna före årsstämman ska ha möjlighet att utöva sin rösträtt genom poströstning. Aktieägare kan därmed välja att utöva sin rösträtt vid stämman personligen, genom ombud eller genom poströstning. A. Rätt att delta på stämman Aktieägare som önskar delta vid årsstämman ska: vara införd i den av Euroclear Sweden AB förda aktieboken måndagen den 20 maj 2024, och anmäla sin avsikt att delta vid stämman till Bolaget i enlighet med anvisningarna under avsnitt ”B. Anmälan för deltagande personligen eller genom ombud” senast onsdagen den 22 maj 2024, eller avge en poströst i enlighet med anvisningarna under rubriken ”C.Anvisningar för poströstning” senast onsdagen den 22 maj 2024. För att ha rätt att del
Notice to attend the 2024 Annual General Meeting of Fingerprint Cards AB (publ)26.4.2024 22:16:32 CEST | Press release
The shareholders of Fingerprint Cards AB (publ), Corp. Reg. No. 556154-2381 (hereinafter referred to as the “Company” or “Fingerprint”)), are hereby invited to attend the Annual General Meeting (“AGM” or the “Meeting”) to be held at 3:00 p.m. on Tuesday, May 28, 2024, at GT30 (meeting room “Bond”), Grev Turegatan 30 in Stockholm. The Board of Directors has decided, pursuant to the Company’s articles of association, that shareholders shall also have the right to exercise their voting rights by postal voting. Shareholders may therefore choose to exercise their voting rights at the Meeting by attending in person, through a proxy or by postal voting. A. Right to participate in the Meeting In order to participate in the Meeting, a shareholder shall: be registered in the register of shareholders maintained by Euroclear Sweden AB as of Monday, May 20, 2024, and give notice of attendance at the Meeting to the Company in accordance with the instructions set out in the section “B. Notice of atte
Fingerprints announces partially guaranteed rights issue of up to approximately SEK 310 million, agreement on early redemption of its convertible bonds, bridge loan of SEK 60 million and preliminary financial information for Q1 202426.4.2024 22:00:00 CEST | Press release
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. The Board of Directors of Fingerprint Cards AB ("Fingerprints" or the "Company") has resolved on a partially guaranteed issue of new shares of series B (“B-shares”) of up to approximately SEK 310 million with preferential rights for its existing shareholders, subject to subsequent approval from the annual general meeting in the Company to be held on 28 May 2024 (the “Rights Issue”). The Rights Issue is subject to subscription undertakings and guarantee commitments in a total amount of up to SEK 275 million. The Board of Directors of Fingerprints has also entered into an agreement with an entity managed by